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Introduction
Most African countries have introduced the pneumo­
coccal conjugate vaccine (PCV) in their childhood 
immunisation programmes, which has led to a sub­
stantial reduction in pneumococcal disease.1,2 Kenya 
introduced the ten­valent PCV (PCV10) in 2011, with 
support from Gavi, the Vaccine Alliance. In Kilifi, a 
coastal area in Kenya with enhanced surveillance 
for bacterial diseases, overall invasive pneumococcal 
disease (IPD) decreased by 68% in the post­vaccination 
period (defined as 2012–16) in children younger than 
5 years.3
Although PCVs are among the most expensive 
vaccines available, Gavi paid for the majority of vaccine 
costs when most African countries introduced PCV.4 
However, countries are expected to transition from 
Gavi support and sub sequently take over the full 
costs once their 3 year average gross national income 
per capita exceeds US$1580. Currently three African 
countries (Angola, Republic of the Congo, and Nigeria)5 
are in the accelerated transition phase,6 and six more 
(Ghana, Côte d’Ivoire, Lesotho, Sudan, Kenya, and 
Zambia) are expected to join within the next 5 years.7–12 
With the increase in PCV costs at the point of transi­
tion, countries will need to independently assess the 
cost­effectiveness and the affordability of sustaining 
PCV use.
Kenya has recently entered the preparatory transition 
phase, which will see the country’s current contri bution 
of $0·21 per dose increase by 15% every year.6 In 2022, 
Kenya will enter the accelerated transition phase, which 
gradually increases the country’s cost contribution to the 
full Gavi price of $3·05 by 2027. In 2027, PCV costs will 
be 15 times higher than current expenditure.6 Hence, 
before entering the accelerated transition phase, Kenya 
will need to evaluate whether to continue or discontinue 
PCV. We aimed to assess the incremental impact and 
cost­effectiveness of continuing PCV.
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Summary
Background In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, 
which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to 
reach the threshold at which countries transition from Gavi support to self-financing (3-year average gross national 
income per capita of US$1580), they will need to consider whether to continue pneumococcal conjugate vaccine 
(PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes. Using Kenya as a case 
study, we assessed the incremental cost-effectiveness of continuing PCV use.
Methods In this modelling and cost-effectiveness study, we fitted a dynamic compartmental model of pneumococcal 
carriage to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya. 
We predicted disease incidence and related mortality for either continuing PCV use beyond 2022, the start of Kenya’s 
transition from Gavi support, or its discontinuation. We calculated the costs per disability-adjusted life-year (DALY) 
averted and associated 95% prediction intervals (PI).
Findings We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD incidence will increase from 
8·5 per 100 000 in 2022, to 16·2 per 100 000 per year in 2032. Continuing vaccination would prevent 14 329 (95% PI 
6130–25 256) deaths and 101 513 (4386–196 674) disease cases during that time. Continuing PCV after 2022 will 
require an estimated additional US$15·8 million annually compared with discontinuing vaccination. We predicted 
that the incremental cost per DALY averted of continuing PCV would be $153 (95% PI 70–411) in 2032.
Interpretation Continuing PCV use is essential to sustain its health gains. Based on the Kenyan GDP per capita of 
$1445, and in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of the 
assumption that any reduction in disease will translate to a reduction in mortality). Although affordability is likely to 
be a concern, our findings support an expansion of the vaccine budget in Kenya.
Funding Wellcome Trust and Gavi, the Vaccine Alliance.
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Methods
Overview
In this study we used a dynamic pneumococcal trans­
mission model in combination with a costing model 
to estimate the cost­effectiveness of the two major policy 
options for PCV use in Kenya from 2022—ie, the 
continuation of PCV use at Gavi’s current and scheduled 
prices, or discontinuation of the vaccine. The approach 
accounts for the uncertainty in both epidemiology and 
costing estimates, and propagates it to the predicted 
outcomes. The study was part of the Pneumococcal 
Conjugate Vaccine Impact Study (PCVIS) approved by 
the Kenya Medical Research Institute (KEMRI) Ethical 
Review Committee (SSC 1433). It has an additional ap­
proval by the Oxford Tropical Research Ethics Committee 
(OXTREC 30­10), with delegated authority from the 
London School of Hygiene & Tropical Medicine (LSHTM) 
Research Ethics Committee.
Disease model and incidence prediction
The details of the transmission model have been 
described elsewhere.13 In brief, we used a com part­
mental, age­structured, dynamic model (appendix). The 
model has a Susceptible­Infected­Susceptible struc ture 
for three sero type groups: the vaccine serotypes, 
strongly competitive non­vaccine serotypes, and weakly 
competitive non­vaccine serotypes. We calibrated the 
model to age­stratified annual pre­vaccination (2009–10) 
and post­vaccination (2011–16) pneumococcal carriage 
prevalence by fitting serotype competition, susceptibility 
to infection if exposed, and vaccine efficacy using non­
informative priors for all parameters except the vaccine 
efficacy (appendix). Estimating competition parameters 
within the observed data increases the validity of the 
projections of serotype replacement disease within the 
model. We did not include the effect of treatment of 
pneumococcal disease on the prevalence of carriage in 
the transmission model in view of the fact that disease is 
very rare compared with carriage (ie, it is unlikely that 
treatment would affect carriage).
In January, 2011, in Kilifi, PCV vaccination was 
introduced together with a catch­up campaign in children 
younger than 5 years. To extrapolate findings to the rest 
of Kenya, where PCV was introduced without a catch­up 
campaign, the fitted model was re­run under these 
conditions. We predicted carriage incidence for a 15­year 
period, from 2017 to 2032. We predicted IPD incidence 
by multiplying modelled age­specific carriage incidence 
with case­to­carrier ratios. For each model posterior, the 
case­to­carrier ratios were calculated as the ratio of the 
observed pre­vaccination IPD incidence at Kilifi County 
Hospital3 to modelled pre­vaccination carriage incidence. 
The case­to­carrier ratios were assumed to remain 
unchanged post­vaccination. The 15­year period was 
chosen because it is a scope of time that the Kenyan 
Government generally uses for long­term health policy 
and strategy documents and its Vision 2030 development 
goals.14,15 15 years is also the usual length of time between 
the publication of results of phase 3 clinical trials and 
licensure and introduction of new vaccines,16 which 
Research in context
Evidence before this study
We searched PubMed, African Journals Online (AJOL), 
and Cochrane Reviews databases for cost-effectiveness studies 
of pneumococcal conjugate vaccine (PCV) in Kenya published 
up to January, 2018. We excluded studies from the search 
results that did not report cost-effectiveness analyses of PCV in 
Kenya. We used the following keywords and their close 
variations in the search strings/logics: pneumococcus; 
conjugate vaccine; vaccination; economic modelling; 
cost-effectiveness; cost-benefit; Kenya; Africa; and Gavi.
Our search identified no previous studies reporting on the 
cost-effectiveness of continuing PCV after Kenya transitions 
from Gavi financial support. One study assessed the 
cost-effectiveness of the ten-valent PCV and 13-valent PCV in 
Kenya in the immediate (5 years) post-introduction period 
(Ayieko P and colleagues, 2012). However, the study did not 
consider whether it would be worth sustaining PCV in the 
period in which disease has reached a new and low-incidence 
equilibrium in a mature PCV era.
Added value of this study
Our study combined transmission and economic modelling to 
estimate the incremental cost-effectiveness of continuing PCV 
at full cost after transitioning from Gavi financial support. 
We found that continuing PCV use will be necessary to sustain 
the gains made in reducing pneumococcal disease and that it is 
cost-effective (based on the Kenyan gross domestic product 
[GDP] per capita of $1445, and compared with other vaccines). 
However, Kenya will need to more than double its current 
overall vaccine procurement budget to continue PCV use. 
Our findings are timely for informing upcoming 
recommendations by the Kenyan National Immunization 
Technical Advisory Group on continued PCV use in Kenya.
Implications of all the available evidence
Our findings suggest that to sustain the benefits of PCV, 
the Kenyan Government needs to make more financial 
commitments towards PCV procurement than it is currently 
spending. An intervention can be cost-effective based on 
common thresholds such as GDP per capita, but that is not 
sufficient to conclude that resources will therefore be made 
available. Our results should be of interest for many 
low-income countries finding themselves in similar 
deliberations but lacking similarly detailed data that we have 
used in our study, or the capacity to synthesise this evidence in 
a cost-effectiveness analysis.
See Online for appendix
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means that it is unlikely that a new vaccine against 
Streptococcus pneumoniae will be licensed and introduced 
in Kenya during this time period.
IPD was defined as isolation of S pneumoniae from 
a sterile site culture in an individual admitted 
to Kilifi County Hospital. We split the predicted IPD 
incidence into the age­dependent proportions that are 
pneumococcal meningitis, pneumococcal sepsis, and 
bacteraemic pneumo coccal pneumonia incidence on 
the basis of the distribution observed in clinical data 
from the hospital (appendix). We defined pneumo­
coccal meningitis as isolation of S pneumoniae from 
cerebrospinal fluid (CSF) or isolation of S pneumoniae 
from blood, accom panied by a CSF white blood cell 
count of 50 × 10⁶ cells per L or greater or a ratio of CSF 
glucose to plasma glucose of less than 0·1. Bacteraemic 
pneumococcal pneumonia was defined as IPD with 
no pneumococcal meningitis but with severe or very 
severe pneumonia (as defined by WHO).17 Pneumococcal 
sepsis was defined as IPD not meeting the definitions of 
pneumococcal meningitis or bacteraemic pneumococcal 
pneumonia. We further assumed that for every case 
of IPD prevented, 4·98 cases of clinically defined 
pneumonia would also be pre vented.3,18 This ratio was 
estimated by dividing the vaccine­preventable clinical 
pneumonia incidence (329 per 100 000 per year)18 by 
vaccine­pre ventable IPD incidence (66·3 per 100 000 per 
year),3 which were both estimated from surveillance at 
Kilifi County Hospital. We included uncertainty in the 
ratio by sampling from normal distributions with 
means (and SDs) equal to the point estimates of vaccine­
preventable IPD and clinical pneumonia incidence 
worked out using the observations at Kilifi County 
Hospital. The hospital surveillance underestimated 
the incidence of pneumonia and menin gitis by 45% 
and 30%, respectively (table 1).19 We accounted for this 
syndrome­independent under­reporting in our analysis 
by inflating case numbers commensurately.
Vaccination programme costs
The programme costs included vaccine costs, vaccine 
wastage, safety boxes, administering syringes for each 
Point estimate Statistical 
distribution
Source
Proportions of patients with access to care
Hospital care for sepsis, bacteraemic pneumonia, and 
non-bacteraemic pneumonia
55% Beta (55,45) Moïsi et al19
Hospital care for meningitis 70% Beta (70,30) Moïsi et al19
Outpatient care for IPD and non-bacteraemic pneumonia 63% Beta (63,37) Källander et al20
Health outcomes
Proportion of patients with meningitis who developed sequelae 25% Beta (25,75) Edmond et al21
Case fatality rate with hospital care
Sepsis, bacteraemic pneumonia and meningitis: children 
(<15 years)
19% Beta (19,81) Kilifi Country Hospital
Sepsis, bacteraemic pneumonia and meningitis: adults 
(≥15 years)
46% Beta (46,54) Kilifi Country Hospital
Non-bacteraemic pneumonia 5·7% Beta (6,94) Berkley et al22
Case fatality rate without hospital care
Meningitis 97% Beta (97,3) Ayieko et al23
Sepsis and bacteraemic pneumonia 50% Beta (4,4) Ayieko et al23
Non-bacteraemic pneumonia 12% Beta (12,88) Ayieko et al23
Vaccination costs (US$)
Vaccine price per dose $0·21–3·05 (appendix) Fixed Gavi, the Vaccine Alliance6,7,24
Safety boxes $0·46 Fixed UNICEF25
Auto-disable syringes $0·045 Fixed UNICEF25
Vaccine delivery cost per dose $1·42 Gamma (4,0·4) Mvundura et al26
Syringe wastage 5% Fixed Ayieko et al23
Vaccine wastage 15% Fixed Gavi, the Vaccine Alliance,23,,27 Parmar et al28
Treatment costs (US$)
With hospital care
Meningitis $357·74 Gamma (4,97) Ayieko et al29
Sepsis, bacteraemic, and non-bacteraemic pneumonia $74·64 Gamma (4,19) Ayieko et al29
With outpatient care (all four disorders) $2·74 Gamma (4,0·75) Larson et al30
Without hospital care (all four disorders) $1·15 Gamma (4,0·3) Larson et al30
IPD=invasive pneumococcal disease.
Table 1: Economic and health parameters included in the probabilistic sensitivity analysis
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dose, syringe wastage, and vaccine delivery cost (table 1). 
Annual vaccine cost was calculated according to Gavi 
transitions rules (appendix). The vaccine delivery cost 
included the vaccine supply chain cost and immunisation 
service delivery cost. The initial investment in expanding 
the cold chain capacity in 2011 was not included. 
A switch from two­dose to four­dose presentation for 
Gavi countries was announced in 2017.27 The four­
dose presentation has a preservative and once opened 
for the first time the vial can be kept for up to 28 days; 
therefore, no noteworthy change in vaccine wastage rates 
is expected.27
Treatment costs
We adopted a societal perspective in our analyses—
ie, including direct medical costs, the opportunity cost of 
caretaker time, and household out­of­pocket costs. To 
apply the appropriate treatment costs, we divided the 
cases into three groups depending on where individuals 
were treated: in hospital, as outpatients, or outside of 
medical care (table 1). All costs not referring to 2016 were 
converted into 2016 US$ for our analysis by using the 
International Monetary Fund’s gross domestic product 
(GDP) deflators for Kenya.31
Disability-adjusted life-years
The treatment costs for the predicted number of cases 
for the four diseases studied and the vaccination cost of 
birth cohorts were estimated and used to calculate the 
costs per disability­adjusted life­year (DALY) averted. We 
calculated the years lost due to disability as the product of 
disease incidence, duration of disease, and disability 
weights.32 We used disability weights from the 2013 
Global Burden of Disease study33 in calculating the 
years lived with disability (YLD) component of DALYs. 
We used the disability weight of 0·133, assigned for 
infectious diseases with severe acute episodes, for both 
IPD and non­bacteraemic pneumonia episodes. For 
meningitis sequelae, we used a disability weight of 
0·542 assigned for motor plus cognitive impairment. We 
assumed a duration of 15 days for all IPD syndromes and 
7 days for non­bacteraemic pneu monia.20 Meningitis 
Figure 1: Model fit to carriage data
Recorded (circles, with 95% credible intervals shown by vertical lines) and predicted (horizontal lines, with 95% predictive intervals shown by shaded areas) carriage prevalence of different vaccine 
serotypes over time. VT=vaccine serotypes. sNVT=strong non-vaccine serotypes. wNVT=weak non-vaccine serotypes.
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sequelae were assumed to last a lifetime.21,34 We used the 
Kenyan age­specific life expectancies35 in calculating the 
years of life lost (YLL) due to death. The discount rate on 
costs and DALYs was set at 3%.
Sensitivity analysis of the cost inputs and disease model
The full uncertainty of both epidemiological and cost 
parameters was propagated to the results as follows: 
for each posterior estimate of the epidemiological model 
we sampled a set of cost parameters from the pre­
set distri butions, effectively combining probabilistic fitting 
of the epidemiological model with a probabilistic sensitivity 
analysis of the costing model (table 1). We performed 
a univariable sensitivity analysis for case­fatality rates, 
access to hospital care rates, and the ratio of vaccine 
preventable clinically­defined pneumonia to vaccine pre­
ventable IPD. We estimated the impact on DALYs averted 
and deaths averted between 2022 and 2032 if these inputs 
were changed by 10% of the original value (an arbitrary 
choice). These variables were chosen either because of 
their direct correlation with mortality, which is a major 
contributor to DALYs, or the number of non­bacteraemic 
pneumococcal pneumonia cases, which forms the largest 
fraction of pneumococcal disease syndromes.
In Kenya, it has been recorded that children who 
are carriers of vaccine­type pneumococci respond less 
well to vaccine than non­carriers.36 To assess structural 
uncertainty in our model, we ran our analyses either 
with or without accounting for hyporesponsiveness. In 
the base case, we estimated a single vaccine efficacy 
independent of carrier status; in the sensitivity analysis, 
vaccine efficacy was estimated separately in vaccine­type 
carriers and in others. We also present two scenarios 
of discounting—ie, discounting both costs and DALYs 
at 3% (base case) or discounting costs alone.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data used and had the final responsibility to send the 
manuscript for publication.
Figure 2: Model fit to IPD incidence data
Recorded (circles, with 95% credible intervals shown by vertical lines) and predicted (horizontal lines with 95% predictive intervals shown by shaded areas) IPD incidence of vaccine serotypes over time. 
IPD=invasive pneumococcal disease. VT=vaccine-serotypes. sNVT=strong non-vaccine serotypes. wNVT=weak non-vaccine serotypes.
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Figure 3: IPD incidence, costs, DALYs, and incremental cost-effectiveness ratio if PCV is continued or discontinued in Kenya, 2022–32
Shaded areas are 95% prediction intervals. Vertical dotted lines indicate Gavi transition stages. DALY=disability-adjusted life-year. IPD=invasive pneumococcal 
disease. PCV=pneumococcal conjugate vaccine.
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Results
There was good agreement between the observed and 
fitted age group and serotype­group specific carriage 
prevalence (figure 1, appendix) and IPD incidence 
(figure 2). Findings of our modelling study suggest that 
if cohorts of children born after the start of Jan 1, 2022 
are no longer vaccinated with PCV, IPD incidence will 
increase from 8·5 per 100 000 in 2022 to 16·2 per 100 000 
per year in 2032, equalling pre­PCV levels (figure 3). 
Alternatively, continuing with PCV is predicted to 
result in additional small reductions in IPD incidence 
to 7·9 per 100 000 per year in 2032, and to avert 14 329 
(95% PI 6130–25 256) deaths and 101 513 (4386–196 674) 
IPD and non­bacteraemic pneu monia cases during the 
11 years considered, as com pared with discontinuing 
PCV in 2022.
If vaccination was stopped in 2022, the estimated 
average annual treatment cost for pneumococcal disease 
in Kenya would be $2·9 million. Otherwise, average 
annual treatment and vaccination costs for continuing 
PCV during 2022–32 were estimated as $18·7 million 
(95% CI 12·9–29·4; table 2). The treatment cost averted 
by continuing PCV from 2022 to 2032 was higher in the 
1–5 year age group (49·6% of the costs averted), for those 
with non­bacteraemic pneumonia (65·9%), and in cases 
treated as inpatients (97·7%; table 3). We predicted 
that discontinuing PCV would partly sustain direct and 
indirect protection from the vaccination of previous 
cohorts for some of the study period, with a gradually 
declining effect on IPD incidence. As a result, we predict 
that continuation of PCV will not be cost­effective initially. 
However, we show that within only 1 year after the decision 
to continue PCV, the incremental cost­effectiveness ratio 
(ICER), in comparison to dis continuing PCV, improves 
substantially towards the threshold of the Kenyan GDP 
per capita ($1455 in 2016) and continues to improve 
throughout the study period (figure 3). Compared with 
discontinuing PCV in 2022, we predicted that in 2032, the 
cost per DALY averted would be $153, the cost per case 
averted $952, and the cost per death averted $6856 
(table 2). The DALYs averted over the period 2022 to 2032 
were higher in the 1–5 year age group (54·0% of the 
DALYs averted), those with non­bacteraemic pneumonia 
(46·9%), cases treated as outpatients (39·9%), and 
mortality (98·1%) compared with morbidity (table 3).
Results of sensitivity analysis showed that when 
using the 2016 Kenyan GDP per capita of $1455 as a 
threshold to determine cost effectiveness, more than 
99·5% of posterior samples indicated that continuation 
of PCV vaccination would be cost effective for just 
under 6 years after 2022 (data not shown). Continuing 
vaccination had a 99·9% probability of being cost­
effective at a willingness to pay per DALY averted of 
$800 (figure 4). Compared with discounting both costs 
and DALYs, discounting costs alone resulted in an 
ICER that was twice as favourable (table 2). Increasing 
the case fatality rates by 10% was estimated to increase 
the DALYs and deaths averted between 2022 and 2032 
by 18 900 and 511, respectively, compared with baseline 
totals of 580 000 and 14 329, respectively. Increasing 
the proportion of cases that accessed hospital care 
by 10% reduced the DALYs and deaths averted by 
34 800 and 870, respectively, while increasing the ratio 
of vaccine­preventable clinically­defined pneumonia to 
vaccine­preventable IPD by 10% in creased the DALYs 
Average annual treatment 
cost, 2022–32, US$ (95% PI)
Cost per DALY averted 
in 2032, US$ (95% PI)
Cost per case averted 
in 2032, US$ (95% PI)
Cost per death averted 
in 2032, US$ (95% PI)
Stopping vaccination in year 2022 2 898 780 
(630 279–8 095 725)
Ref Ref Ref
Continuing vaccination 18 747 118 
(12 850 031–29 392 111)
153 (70–411) 952 (302–5688) 6856 (3144–8464)
Continuing vaccination (discounting costs only) 18 747 118 
(12 850 031–29 392 111)
72 (33–196) 575 (183–3442) 4148 (1901–11 171)
DALY=disability-adjusted life year. Ref=reference intervention or strategy.
Table 2: Estimated costs and cost-effectiveness ratios for different scenarios
Treatment cost averted, 2022–32, 
US$ (95% PI)
DALYs averted, 2022–32, 
(95% PI)
Age group, years
<1 1 950 585 (306 762 to 6 022 265) 98 042 (24 860 to 210 299)
1–5 5 536 181 (916 766 to 16 387 094) 312 198 (128 126 to 565 969)
6–14 1 807 771 (454 777 to 4 694 186) 85 087 (37 529 to 149 149)
15–20 138 474 (36 385 to 351 701) 7491 (3960 to 12 241)
21–49 1 149 221 (289 609 to 2 992 496) 56 268 (29 450 to 92 727)
50+ 579 816 (96 867 to 1 718 939) 18 685 (9283 to 31 832)
Disorder
Meningitis 2 121 683 (617 639 to 5 255 538) 74 642 (50 769 to 96 115)
Sepsis 880 777 (274 687 to 2 119 485) 125 713 (78 008 to 185 066)
Bacteraemic pneumonia 750 696 (229 347 to 1 841 014) 107 118 (56 084 to 172 029)
Non-bacteraemic pneumonia 7 266 638 (1 119 166 to 25 663 651) 272 115 (–53 007 to 668 776)
Type of care
Inpatient 10 850 030 (2 276 101 to 31 083 016) 213 734 (90 487 to 404 828)
Outpatient 212 093 (7451 to 735 443) 223 871 (88 058 to 443 001)
No hospital care 43 216 (360 to 233 991) 123 679 (24 683 to 322 589)
Mortality versus morbidity
Morbidity ·· 10 623 (6382 to 15 497)
Mortality ·· 570 063 (241 034 to 1 012 605)
Table 3: Treatment costs and DALYs averted by age group, disorder, type of care, and morbidity versus 
mortality
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and deaths averted by 36 900 and 920, respectively, 
between 2022 and 2032.
We estimated that the effect of hyporesponsiveness was 
relatively small. Vaccine serotype carriers had a vaccine 
efficacy estimate against carriage that was 4 percentage 
points lower than that for other vaccines (appendix); as 
such, omitting this mechanism in the model structure 
led to similar results (appendix). Therefore, we did not 
include hyporesponsiveness in our final model.
Discussion
Like several other low­income countries, Kenya will 
soon be expected to take over the full cost of national 
pneumococcal conjugate vaccination procurement. In 
this study, we have estimated the cost­effectiveness of 
continuing PCV using Gavi’s schedule of vaccine prices, 
which will reach a peak at $3·05 per dose in 2027, at 
which point Kenya will become fully self­financing. Our 
model projects that discontinuing PCV would lead to an 
increase in IPD burden equivalent to pre­vaccination 
levels within 10 years. Initially, continuing vaccination 
might not be cost­effective because of the benefits accrued 
through vaccination of previous cohorts. However, the 
cost­effectiveness becomes substantially more favourable 
within a few years and, by 2032, the cost (in 2016 US$) 
plateaus at $153 (95% PI $70–$411) per discounted DALY 
averted.
The most commonly used threshold for judging the 
cost­effectiveness of an intervention is a country’s GDP 
per capita. Using this criterion, we find continuation of 
PCV in Kenya after transition from Gavi support highly 
cost­effective. The GDP per capita threshold was initially 
supported by the Commission on Macroeconomics and 
Health37 and adopted by WHO’s Choosing Interventions 
that are Cost­Effective project (WHO­CHOICE). The 
use of GDP­based thresholds has been criticised for 
four main reasons: it does not consider the cost–benefit 
profile of interventions competing for the same health 
budget; it does not adequately address the willingness 
to pay; it does not address affordability; and it is too 
easily attained.38 Alternatives include benchmarking of 
interventions by assessing a country’s willingness to pay 
by comparing cost­effectiveness ratios against that of 
vaccines currently in use.38
The cumulative costs per DALY averted of introducing 
the Rotarix or the RotaTeq rotavirus vaccines in Kenya 
have been estimated as $200 and $406 (2016 US$), 
respectively.39 Similar to our estimates, these were derived 
on the basis of a societal perspective with a 3% discounting 
of both costs and benefits.39 The Haemophilus influenzae 
type b (Hib) vaccine was introduced in 2001 in Kenya as 
part of the pentavalent vaccine.40 In a static model 
developed to follow the Kenyan 2004 birth cohort until 
death, with and without Hib vaccine, it was estimated 
that the discounted (3% for both costs and benefits) cost 
per DALY averted of introducing Hib vaccine was 
$85 (2016 US$) from a health provider perspective.41 This 
calculation suggests that continuation of PCV is less cost­
effective than the Hib vaccine and more cost­effective 
than the rotavirus vaccine. However, these comparisons 
must be tempered by the fact that the rotavirus analysis 
ignored herd immunity, while the Hib analysis took 
a health provider perspective, both of which decrease 
cost­effectiveness.
However, cost­effectiveness does not necessarily imply 
affordability. The latter depends on available resources 
in the health budget, or any other sources within the 
national accounts that can fill the gap in the health 
budget. Budgetary allocation to the health sector as a 
fraction of national government budget has slightly 
decreased from 4% in the financial year 2014–15 to 
3·7% in the financial year 2016–17.42 The Kenyan annual 
health budget for 2015 was $600 million.42 Of this, 
$6·9 million (0·8%)43 was spent on vaccines. This has 
been possible because Kenya only needs to fund 10% of 
its vaccines from its revenues; donors fund the rest of the 
budget.7 We have estimated that continuing with PCV 
after 2022 will require an additional $15·8 million 
annually compared with discontinuing PCV; in other 
words, it will more than double Kenya’s current 
expenditure on vaccines. At the same time, following 
transition from Gavi support, the Kenyan Government’s 
financial contribution for pentavalent, rotavirus, and 
yellow fever vaccines will need to increase as well if 
Kenya wants to sustain its current vaccine portfolio.
Several initiatives indicate that the cost of PCV 
procurement might be reduced in the future. For instance, 
the Serum Institute of India is developing a ten­valent 
PCV with a target per­dose price of $2·00.44 Also, in 
settings where vaccine serotypes have been eliminated 
from circulation, it might be possible to sustain control 
Figure 4: Cost-effectiveness acceptability curve
Probability of continuing pneumococcal conjugate vaccine being cost-effective 
against the willingness to pay per DALY averted. DALY=disability adjusted life-year.
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of transmission using a two­dose or even one­dose 
schedule.45 If vaccine serotypes can be eliminated in 
Kenya—for example by additional efforts such as a catch­
up campaign—then the shift to a reduced dose schedule 
might also be feasible. By 2022, most of these options will 
have a wider evidence base that might allow their formal 
consideration. Currently there is insufficient support to 
include them in our analyses, but if proven to be effective, 
these aspects will further improve on our PCV cost­
effectiveness estimates of sustaining PCV in Kenya.
There are potential limitations to our study. The 
proportion of individuals with pneumococcal disease 
treated in hospital, as outpatients, or those who do not 
access care is a key determinant of both costs incurred 
and DALYs, by determining the case fatality rate. 
Overestimating the proportion of cases that get hospital 
treatment would mean that the overall costs of treatment 
were overestimated while the fatal cases, and therefore 
DALYs, were underestimated. The overall effect would be 
an overestimated ICER, which is conservative. In our 
analysis, we estimated the proportion of cases that were 
treated in hospital using local sur veillance data. However, 
we did not have local information about what proportion 
among non­hospitalised cases are treated as outpatients; 
this was obtained from a Ugandan verbal autopsy 
study among fatal pneumonia cases.20 It is possible, 
therefore, that we have overestimated the number of 
non­hospitalised patients treated as outpatients, and, by 
extension, overestimated the ICER. The case­fatality rate 
for disease cases that do not access hospital care was 
obtained from a study23 that had used expert opinion for 
the measure. The lack of data on this input persists. We 
have estimated that a 10% increase or decrease in case­
fatality rates leads to an increase or decrease in DALYs 
and deaths averted between 2022 and 2032 by 18 900 
and 511, compared with baseline totals of 580 000 and 
14 329, respectively; these changes are about 3·3% and 
3·6% of the baseline totals, respectively.
In our study, carriage prevalence used in model fitting 
and IPD incidence data were obtained from Kilifi, but we 
made inferences about the rest of the country. This raises 
the question: how representative is Kilifi of the rest of 
Kenya in terms of health and health system indicators? 
Using under­5 mortality as a crude index of health, Kilifi 
does not stand out, with a rate of 72 per 1000 livebirths 
compared with the national estimates of 79 per 1000.46 
The national mean annual rate of cases hospitalised 
with severe acute respiratory illness of 228·1 (95% CI 
208·1–249·4) per 100 000 people is similar to that of the 
coastal region, 213·3 (193·5–234·7) per 100 000 people, 
which covers Kilifi.47 In a service avail ability and readi­
ness assessment report for Kenya,48 the mean availability 
of services for eliminating com municable conditions 
was 54% nationwide and 51% in Kilifi county. The 
national health facility density per 10 000 population was 
2·04 compared with 1·99 in Kilifi county.48 In Kenya, the 
annual number of visits to health­care providers per 
person was 3·1, and 12·7% of people reported sickness 
but did not seek health care; in Kilifi the estimates were 
3·0 and 10·8%, respectively.49
We included vaccine impact on clinically defined 
pneumonia but not on otitis media and sinusitis; hence 
our estimates of impact are conservative. We extrapolated 
the impact of PCV10 on clinically­defined pneumonia 
from its effect on IPD. We estimated the ratio of the 
vaccine­preventable disease incidence (VPDI) for IPD 
to the VPDI for clinically­defined pneumonia from 
surveillance data in Kilifi, Kenya, following PCV10 
introduction.18 Our estimate (4·98, 95% UI 0·27–8·91) is 
lower than the ratio of IPD to pneumonia in other settings. 
For example, radiologically­confirmed pneumonia was 
estimated to be 7·5 times more common than IPD in a 
clinical trial in The Gambia;50 all­cause pneumonia was 
estimated to be 216 times more common than IPD in the 
USA.51 Much higher values for this ratio are probably a 
reflection of a lower prevalence of pneumococcal disease 
among the chosen case definition, leading to a lower 
positive predictive value for pneumococcal aetiology. The 
internal validity of our own estimate is underpinned by 
the fact that it was derived using the same surveillance 
setting for both IPD and clinically­defined pneumonia.
Cost­effectiveness analyses are strongly affected by the 
effect of the intervention on mortality and yet data on 
mortality impacts are relatively sparse, especially in 
countries that lack cause­specific vital registration 
systems such as Kenya. We estimated the mortality 
impact of PCV10 by multiplying the incidence of cases 
with different pneumococcal syndromes by the case 
fatality ratio for that syndrome. The case fatality ratios 
were adjusted according to whether the patient received 
inpatient care. Therefore, our cost­effectiveness analysis 
is largely based on the assumption that reduction in 
disease will translate to reduction in mortality. The 
rationale for using a vaccine with limited serotype 
coverage is that non­vaccine sero types, which can cause 
serotype replacement disease, will have a lower case 
fatality ratio than the vaccine serotypes that they replace. 
If so, then our approach, which uses a constant case 
fatality ratio, will provide a conservative estimate of cost­
effectiveness.
Findings of a meta­analysis of case fatality ratios for 
pneumococcal pneumonia showed that patients with 
pneumonia caused by PCV10 serotypes 6B and 19F and 
non­vaccine serotypes 3, 6A, and 9N were significantly 
more likely to die than patients with serotype 14 
(the reference serotype in the study) and that patients 
infected with vaccine serotypes 1 and 7F and non­
vaccine serotype 8 were significantly less likely to die.52 
Serotypes 3 and 6A have been recorded in carriage in 
Kenya post vaccination,53 but have not been associated 
with increased IPD in the period.3 Hence, there was 
no clear evidence from the meta­analysis as to whether 
non­vaccine serotypes as a group have a higher case 
fatality ratio than vaccine­serotypes because the analysis 
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was serotype­specific. If the case fatality ratio of non­
vaccine serotypes is higher than vaccine serotypes, this 
would abrogate any mortality benefits attributable to the 
effect of PCV10 on vaccine serotype disease. However, in 
the UK, IPD­related mortality rate in children younger 
than 5 years decreased by 69% following PCV7 and 
PCV13 introduction,54 despite documented rapid serotype 
replacement in disease.55
In conclusion, several low­income countries will soon 
be transitioning out of Gavi support and will need to 
decide whether to sustain their pneumococcal conjugate 
vaccination. We show, using Kenya as an example, 
how ongoing detailed surveillance can be combined 
with mathematical modelling and health economics to 
inform an upcoming decision of a country’s National 
Immunization Technical Advisory Group on the cost­
effectiveness of different policy options. We estimate 
that maintaining PCV is essential to sustain the 
decreased burden of pneumococcal disease and that it is 
cost­effective against conventional criteria. For Kenya, 
affording PCV vaccination in the post­Gavi era will 
necessitate the country substantially increasing the 
proportion of health spending on routine immunisation.
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